Industry
Biotechnology
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 12:17 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 10:59 am
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 10:13 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Insights
September 03, 2024 | 7:00 pm
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 4:13 pm
Portfolio Pulse from Benzinga Newsdesk
September 03, 2024 | 12:20 pm
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 4:42 pm
Portfolio Pulse from Benzinga Newsdesk
August 21, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
August 13, 2024 | 8:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.